Dosell AB Granted European Patent in Data-Driven Medication Management
iZafe Group AB (publ) today announces that its subsidiary Dosell AB has been granted a European patent, EP4228584, titled “Medication Delivery”. The patent strengthens iZafe Group’s long-term position within data-driven and personalized healthcare and represents an important part of the company’s continued development of digital care solutions, including its new remote care system.
The patent covers a system where patient data from sensors is analyzed to identify changes in health status. Based on this information, medication treatment can be adjusted over time, enabling more personalized and proactive care.
Although the patent is not directly linked to Dosell’s current functionality, it aligns with iZafe Group’s strategic direction of combining medical technology, data, and future AI-based analytics.
Through this patent, the company strengthens:
- its technological platform for future solutions
- its intellectual property value
- its position within a growing global healthcare segment
In the long term, the technology enables solutions where treatment can be optimized based on real patient data, contributing to improved patient safety and more efficient healthcare.
“This patent is an important step in our long-term strategy. It clearly demonstrates the direction we are moving in—towards more data-driven, intelligent, and personalized healthcare. At the same time, it strengthens our intellectual property and future potential,” says Anders Segerström, CEO of iZafe Group.
